Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in VVOS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 1.1M | $1.3M | — | 18.947% | 0.04% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 96K | $113K | +69.7% | 1.622% | 0.00% |
| 3 | COMMONWEALTH EQUITY SERVICES, LLC | 43K | $50K | +4.9% | 0.722% | 0.00% |
| 4 | IHT Wealth Management, LLC | 41K | $48K | — | 0.697% | 0.00% |
| 5 | Centurion Wealth Management LLC | 36K | $42K | — | 0.606% | 0.01% |
| 6 | National Asset Management, Inc. | 38K | $41K | -12.6% | 0.646% | 0.00% |
| 7 | BlackRock, Inc. | 28K | $33K | 0.0% | 0.472% | 0.00% |
| 8 | XTX Topco Ltd | 25K | $30K | — | 0.426% | 0.00% |
| 9 | STATE STREET CORP | 25K | $29K | 0.0% | 0.423% | 0.00% |
| 10 | Sequoia Financial Advisors, LLC | 24K | $28K | — | 0.407% | 0.00% |
| 11 | Acorn Wealth Advisors, LLC | 15K | $17K | 0.0% | 0.251% | 0.01% |
| 12 | NORTHERN TRUST CORP | 13K | $15K | 0.0% | 0.212% | 0.00% |
| 13 | UBS Group AG | 11K | $13K | -12.9% | 0.188% | 0.00% |
| 14 | Tower Research Capital LLC (TRC) | 7K | $9K | +149.2% | 0.125% | 0.00% |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 1K | $1K | 0.0% | 0.019% | 0.00% |
| 16 | SIGNATUREFD, LLC | 547 | $645 | 0.0% | 0.009% | 0.00% |
| 17 | Blue Trust, Inc. | 160 | $189 | 0.0% | 0.003% | 0.00% |
| 18 | Kozak & Associates, Inc. | 49 | $60 | 0.0% | 0.001% | 0.00% |
| 19 | MORGAN STANLEY | 7 | $8 | 0.0% | 0.000% | 0.00% |
| 20 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 3 | $4 | — | 0.000% | 0.00% |
| 21 | CITIGROUP INC | 1 | $1 | 0.0% | 0.000% | 0.00% |
| 22 | ROYAL BANK OF CANADA | 4 | $0 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in VVOS — a direct measure of their conviction.
Filings activity in VVOS during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 22 | +22% | 53.08% | +20.41 pp | $2M | +62% |
| Q4 2025 | 18 | 18% | 32.67% | 22.95 pp | $1M | 41% |
| Q3 2025 | 22 | +16% | 55.62% | +21.82 pp | $2M | +65% |
| Q2 2025 | 19 | 14% | 33.80% | 18.03 pp | $1M | 35% |
| Q1 2025 | 22 | +10% | 51.83% | +8.37 pp | $2M | +19% |
| Q4 2024 | 20 | 17% | 43.46% | +26.37 pp | $1M | +154% |
| Q3 2024 | 24 | +20% | 17.09% | +5.36 pp | $1M | +46% |
| Q2 2024 | 20 | — | 11.73% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying VVOS stock.
Based on Q1 2026 13F filings, institutional ownership of Vivos Therapeutics, Inc. stands at 53.1%, held across 22 reporting institutions.
ARMISTICE CAPITAL, LLC is the largest reported institutional holder of VVOS, with approximately 1,115,859 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of VVOS.
Our composite Smart Money Score for VVOS is 55 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
6 institutions opened new positions in VVOS during Q1 2026, while 2 fully exited. 1 added to existing positions and 14 trimmed.
VVOS institutional ownership rose by 20.41 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 96.9% of all reported 13F value in VVOS, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Vivos Therapeutics, Inc. (VVOS) Institutional Ownership